Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02623322 · ClinicalTrials.gov registry record · Phase 2
A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT02623322 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 124 participants.
The verdict
NCT02623322, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
This is a Phase 2, randomized, double-blind, placebo-controlled single dose study in otherwise healthy adults with acute uncomplicated seasonal influenza A to assess the safety and tolerability, efficacy, and pharmacokinetics of MHAA4549A.
Interventions
- DRUG Placebo
- DRUG MHAA4549A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2016-10-12 |
| Est. Completion | 2017-11-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02623322
The ClinicalTrials.gov registry entry for NCT02623322 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02623322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02623322 about?
NCT02623322 is a clinical study titled "A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults". This is a Phase 2, randomized, double-blind, placebo-controlled single dose study in otherwise healthy adults with acute uncomplicated seasonal influenza A to assess the safety and tolerability, efficacy, and pharmacokinetics of MHAA4549A.
What is the current status of trial NCT02623322?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2016-10-12. Estimated completion is 2017-11-13.
What interventions are being tested in trial NCT02623322?
The interventions under investigation include: Placebo (DRUG), MHAA4549A (DRUG).
Who is sponsoring clinical trial NCT02623322?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.